Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 712-722

  Choi, N C ^a   Carey, R W ^a   Daly, W ^a   Mathisen, D ^a   Wain, J ^a   Wright, C ^a   Lynch, T ^a   Grossbard, M ^a   Grillo, H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; VINBLASTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DYSPHAGIA; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; NEUTROPENIA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031034334     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.712     Document Type: Article

References (37)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistics, 1996. CA 46:5-27, 1996
2. Mountain CF: A new international staging system for lung cancer. Chest 89:225-232, 1986 (suppl)
3. Choi NC, Doucette JA: Improved survival of patients with unresectable non-small cell bronchogenic carcinoma by an innovated high-dose en-bloc radiotherapeutic approach. Cancer 48:101-109, 1981
4. Pearson FG, DeLarue NC, Ilves R, et al.: Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 83:1-11, 1982
5. Wilkins EW Jr, Saita S: Surgery for lung cancer: The Massachusetts General Hospital experience, in Choi NC, Grillo HC (eds): Thoracic Oncology. New York, NY, Raven, 1983, pp 115-127
6. Dillman RO, Seagren SL, Herndon J, et al.: Cancer and Leukemia Group B: Randomized trial of induction chemotherapy plus radiation therapy vs radiation therapy alone in stage III non-small cell lung cancer: Five year follow up of CALGB 8433. Proc Am Soc Clin Oncol 12:329, 1993 (abstr 1092)
7. Arriagada R, Le Chevalier T, Quoix E, et al.: ASTRO Plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients. Int J Radiat Oncol Biol Phys 20:1183-1190, 1991
8. Le Chevalier T, Arriagada R, Tarayre M, et al.: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Natl Cancer Inst 84:58, 1992 (letter)
9. Schaake-Koning C, Van den Bogaert W, Dalesio O, et al.: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524-530, 1992
10. Faber LP, Kittle CF, Warren WH, et al.: Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 47:669-677, 1989
11. Ginsberg RJ: Multimodality therapy for stage IIIA (N2) lung cancer: An overview. Chest 103:356S-359S, 1993
12. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91, 1979
13. Douple EB, Richmond RC: Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. Int J Radiat Oncol Biol Phys 8:501-503, 1980
14. Vokes E, Wichselbaum R: Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors. J Clin Oncol 8:911-934, 1990
15. Withers HR: Biologic basis for altered fractionation schemes. Cancer 55:2086-2095, 1985
16. Peters LJ, Ang KK: Unconventional fractionation schemes in radiotherapy, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1986, pp 269-286
17. Strauss G, Herndon JE, Sherman D, et al.: Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage 111A non-small cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase 11 study. J Clin Oncol 10:1237-1244, 1992
18. Boysen PG, Harris JO, Block AJ, et al.: Prospective evaluation for pneumonectomy using perfusion scanning: Follow-up beyond one year. Chest 80:163-166, 1981
19. Choi NC, Kanarek DJ, Kazemi H: Physiologic changes in pulmonary function after thoracic radiotherapy for patients with lung cancer and role of regional pulmonary function studies in predicting postradiotherapy pulmonary function before radiotherapy. Cancer Treat Symp 2:119-130, 1985
20. Diem K, Lentner C (eds): Scientific Tables. Ardsley, NY, Geigy Pharmaceuticals, 1970, p 184
21. Spiegel MR: Probability and Statistics. New York, NY, McGraw-Hill, 1995, p 207
22. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 53:457-481, 1958
23. Fleck J, Camargo J, Godoy D, et al.: Chemoradiation therapy alone versus chemotherapy alone as a neoadjuvant treatment for stage III non-small cell lung cancer. Preliminary report of a phase III, randomized trail. Proc Am Soc Clin Oncol 12:333, 1993 (abstr 1108)
24. Rusch VW, Albain KS, Crowley JJ, et al.: Surgical resection of stage IIIA and IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy: A Southwest Oncology Group trial. J Thorac Cardiovasc Surg 105:97-106, 1993
25. Albain KS, Rusch VW, Crowley JJ, et al.: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880-1892, 1995
26. Sugarbaker DJ, Herndon J, Kohman LJ, et al.: Results of Cancer and Leukemia Group B protocol 8935: A multi-institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg 109:473-485, 1995
27. Burkes RL, Ginsberg RJ, Sheperd FA, et al.: Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: Results of the Toronto phase II trial. J Clin Oncol 10:580-586, 1992
28. Burkes RL, Sheperd FA, Ginsberg RJ, et al.: Induction chemotherapy with MVP in patients with stage III (T1-3,N2,M0) unresectable non-small-cell lung cancer: The Toronto experience. Proc of Am Soc Clin Oncol 13:327, 1994 (abstr 1078)
29. Gralla RJ: Preoperative and adjuvant chemotherapy in non-small cell lung cancer. Semin Oncol 15:8-12, 1988
30. Martini N, Kris M, Flehinger BJ, et al.: Preoperative chemotherapy for stage IIIa (n2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55:1365-1374, 1993
31. Green M, Brodin O, Choi N, et al.: Pre-operative and postoperative treatments in stage III NSCLC. Lung Cancer 10:S15-S17, 1994 (suppl 1)
32. Bunn PA: The treatment of non-small cell lung cancer: Current perspectives and controversies, future directions. Semin Oncol 21:49-59, 1994
33. Ihde DC: Chemotherapy combined with chest irradiation for locally advanced non-small cell lung cancer. Ann Intern Med 115:737-739, 1991
34. Tishler RB, Schiff PB, Geard CR, et al.: Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617, 1992
35. Langer CS, Curran WJ, Keller SM, et al.: Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy). infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer. Int J Radiat Oncol Biol Phys 26:169-478, 1993
36. Vafai D, Israel V, Zaretsky S, et al.: Phase I/II trial of combination carboplatin and Taxol in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:352, 1995 (abstr 1067)
37. Intergroup Study 0139: A phase III comparison between concurrent chemotherapy plus radiotherapy, and concurrent chemotherapy plus radiotherapy followed by surgical resection for stage IIIA (N2) non-small cell lung cancer.